Caroline K Kramer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7690546/publications.pdf

Version: 2024-02-01

39 papers

2,474 citations

20 h-index 35 g-index

39 all docs 39 docs citations

39 times ranked

4276 citing authors

#	Article	IF	CITATIONS
1	Are Metabolically Healthy Overweight and Obesity Benign Conditions?. Annals of Internal Medicine, 2013, 159, 758.	3.9	787
2	Effect of artificial pancreas systems on glycaemic control in patients with type 1 diabetes: a systematic review and meta-analysis of outpatient randomised controlled trials. Lancet Diabetes and Endocrinology,the, 2017, 5, 501-512.	11.4	348
3	Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. Lancet, The, 2014, 384, 2228-2234.	13.7	336
4	Liraglutide and the Preservation of Pancreatic \hat{l}^2 -Cell Function in Early Type 2 Diabetes: The LIBRA Trial. Diabetes Care, 2014, 37, 3270-3278.	8.6	115
5	Fetal Sex and Maternal Risk of Gestational Diabetes Mellitus: The Impact of Having a Boy. Diabetes Care, 2015, 38, 844-851.	8.6	112
6	Each Degree of Glucose Intolerance in Pregnancy Predicts Distinct Trajectories of \hat{l}^2 -Cell Function, Insulin Sensitivity, and Glycemia in the First 3 Years Postpartum. Diabetes Care, 2014, 37, 3262-3269.	8.6	89
7	Sex of the baby and risk of gestational diabetes mellitus in the mother: a systematic review and meta-analysis. Diabetologia, 2015, 58, 2469-2475.	6.3	62
8	Prospective Associations of Vitamin D Status With \hat{I}^2 -Cell Function, Insulin Sensitivity, and Glycemia: The Impact of Parathyroid Hormone Status. Diabetes, 2014, 63, 3868-3879.	0.6	49
9	The Impact of Chronic Liraglutide Therapy on Glucagon Secretion in Type 2 Diabetes: Insight From the LIBRA Trial. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 3702-3709.	3.6	49
10	Maternal Serum Prolactin and Prediction of Postpartum \hat{l}^2 -Cell Function and Risk of Prediabetes/Diabetes. Diabetes Care, 2016, 39, 1250-1258.	8.6	49
11	Predictors of sustained drug-free diabetes remission over 48â€weeks following short-term intensive insulin therapy in early type 2 diabetes. BMJ Open Diabetes Research and Care, 2016, 4, e000270.	2.8	47
12	Vitamin D and Parathyroid Hormone Status in Pregnancy: Effect on Insulin Sensitivity, \hat{l}^2 -cell Function, and Gestational Diabetes Mellitus. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 4506-4513.	3.6	44
13	Evaluation of Circulating Determinants of Beta-Cell Function in Women With and Without Gestational Diabetes. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 2683-2691.	3.6	44
14	Metabolic Impact of Intermittent Fasting in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Interventional Studies. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 902-911.	3.6	41
15	Sodium–Glucose Cotransporter–2 (SGLT-2) Inhibitors and the Treatment of Type 2 Diabetes. Annual Review of Medicine, 2019, 70, 323-334.	12.2	34
16	Comparison of New Glucose-Lowering Drugs on Risk of Heart Failure in TypeÂ2ÂDiabetes. JACC: Heart Failure, 2018, 6, 823-830.	4.1	33
17	Efficacy of glucagonâ€ike peptideâ€1 receptor agonists compared to dipeptidyl peptidaseâ€4 inhibitors for the management of type 2 diabetes: A metaâ€analysis of randomized clinical trials. Diabetes, Obesity and Metabolism, 2018, 20, 68-76.	4.4	32
18	Classes of antihypertensive agents and mortality in hypertensive patients with type 2 diabetesâ€"Network meta-analysis of randomized trials. Journal of Diabetes and Its Complications, 2016, 30, 1192-1200.	2.3	31

#	Article	IF	CITATIONS
19	Insulin and insulin analogs as antidiabetic therapy: A perspective from clinical trials. Cell Metabolism, 2021, 33, 740-747.	16.2	27
20	Why do men have worse COVID-19-related outcomes? A systematic review and meta-analysis with sex adjusted for age. Brazilian Journal of Medical and Biological Research, 2022, 55, e11711.	1.5	22
21	Twoâ€year trial of intermittent insulin therapy vs metformin for the preservation of βâ€cell function after initial shortâ€term intensive insulin induction in early type 2 diabetes. Diabetes, Obesity and Metabolism, 2018, 20, 1399-1407.	4.4	20
22	Effects of individual micronutrients on blood pressure in patients with type 2 diabetes: a systematic review and meta-analysis of randomized clinical trials. Scientific Reports, 2017, 7, 40751.	3.3	18
23	The Relationship Between Parathyroid Hormone and 25-Hydroxyvitamin D During and After Pregnancy. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 1729-1736.	3.6	16
24	Effect of Short-term Intensive Insulin Therapy on Post-challenge Hyperglucagonemia in Early Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 2987-2995.	3.6	15
25	Effect of chronic liraglutide therapy and its withdrawal on time to postchallenge peak glucose in type 2 diabetes. American Journal of Physiology - Endocrinology and Metabolism, 2018, 314, E287-E295.	3.5	13
26	Shortâ€term intensive insulin as induction and maintenance therapy for the preservation of betaâ€cell function in early type 2 diabetes (<scp>RESETâ€IT Main</scp>): A 2â€year randomized controlled trial. Diabetes, Obesity and Metabolism, 2021, 23, 1926-1935.	4.4	8
27	Antepartum determinants of rapid earlyâ€life weight gain in term infants born to women with and without gestational diabetes. Clinical Endocrinology, 2014, 81, 387-394.	2.4	7
28	Sodium–glucose co-transporter-2 (SGLT-2) inhibitors in patients with type 2 diabetes mellitus: the road ahead. European Heart Journal, 2016, 37, 3201-3202.	2,2	7
29	Patient-centered Management of Type 2 Diabetes Mellitus Based on Specific Clinical Scenarios: Systematic Review, Meta-analysis and Trial Sequential Analysis. Journal of Clinical Endocrinology and Metabolism, 2020, 105, .	3.6	6
30	Weight Loss Is a Useful Therapeutic Objective. Canadian Journal of Cardiology, 2015, 31, 211-215.	1.7	4
31	Intermittent Intensive Insulin Therapy for Type 2 Diabetes: Effects on Hypoglycemia, Weight Gain, and Quality of Life Over 2 Years. Endocrine Practice, 2019, 25, 899-907.	2.1	3
32	Meta-analysis of artificial pancreas trials: methodological considerations – Authors' reply. Lancet Diabetes and Endocrinology,the, 2017, 5, 685-686.	11.4	2
33	Stability of insulin and Câ€peptide measurement with longâ€ŧerm frozen storage of serum: Implications for diabetes research studies. Diabetes, Obesity and Metabolism, 2019, 21, 1058-1060.	4.4	2
34	Response to Comment on Kramer et al. Glucagon Response to Oral Glucose Challenge in Type 1 Diabetes: Lack of Impact of Euglycemia. Diabetes Care 2014;37:1076–1082. Diabetes Care, 2014, 37, e209-e209.	8.6	1
35	Clinical Decision Making in Patients With Thyroid Nodules. JAMA Internal Medicine, 2014, 174, 1005.	5.1	1
36	Response to Comment on Kramer et al. Glucagon Response to Oral Glucose Challenge in Type 1 Diabetes: Lack of Impact of Euglycemia. Diabetes Care 2014;37:1076–1082. Diabetes Care, 2014, 37, e225-e225.	8.6	0

#	Article	IF	CITATIONS
37	Response to Comment on Retnakaran et al. Liraglutide and the Preservation of Pancreatic β-Cell Function in Early Type 2 Diabetes: The LIBRA Trial. Diabetes Care 2014;37:3270–3278. Diabetes Care, 2015, 38, e26-e26.	8.6	0
38	Response to Letter to the Editor from Varady et al: "Metabolic Impact of Intermittent Fasting in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Interventional Studies― Journal of Clinical Endocrinology and Metabolism, 2021, 106, e4302-e4303.	3.6	O
39	Response to the Letter to the Editor from Fuller: "Metabolic Impact of Intermittent Fasting in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Interventional Studies― Journal of Clinical Endocrinology and Metabolism, 2021, 106, e4306-e4306.	3.6	0